Bausch And Lomb patents expiration
1. Alrex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4996335 (Pediatric) | BAUSCH AND LOMB | Soft steroids having anti-inflammatory activity |
Sep, 2012
(11 years ago) | |
| US5540930 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
| US5747061 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
|
US5747061 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
|
US5540930 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 09 March, 1998
Treatment: Alrex ophthalmic suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Dosage: SUSPENSION/DROPS;OPHTHALMIC
ALREX family patents
2. Besivance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5447926 | BAUSCH AND LOMB | Quinolone carboxylic acid derivatives |
Apr, 2016
(8 years ago) | |
| US8481526 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Jan, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6699492 | BAUSCH AND LOMB | Quinolone carboxylic acid compositions and related methods of treatment |
Mar, 2019
(5 years ago) | |
| US6685958 | BAUSCH AND LOMB | Quinolone carboxylic acid compositions and related methods of treatment |
Jun, 2021
(2 years ago) | |
| US8937062 | BAUSCH AND LOMB | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria |
Nov, 2029
(5 years from now) | |
| US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(5 years from now) | |
| US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2014 |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
NCE-1 date: 28 May, 2013
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS;OPHTHALMIC
BESIVANCE family patents
3. Istalol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6335335 | BAUSCH AND LOMB | Prolonged-action eye drop |
Nov, 2018
(5 years ago) | |
| US6645963 | BAUSCH AND LOMB | Prolonged-action eye drop |
Nov, 2018
(5 years ago) | |
Drugs and Companies using TIMOLOL MALEATE ingredient
Market Authorisation Date: 04 June, 2004
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
ISTALOL family patents
4. Lotemax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4996335 (Pediatric) | BAUSCH AND LOMB | Soft steroids having anti-inflammatory activity |
Sep, 2012
(11 years ago) | |
| US5540930 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
| US5747061 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
|
US5747061 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
|
US5540930 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 09 March, 1998
Treatment: Lotemax ophthalmic suspension is indicated for the treatment of steroid responsive conditions of the palpebral bulbar conjunctiva, cornea and anterior segment of the globe.
Dosage: SUSPENSION/DROPS;OPHTHALMIC
LOTEMAX family patents
5. Miochol-e patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6261546 | BAUSCH AND LOMB | Methods and compositions for stabilizing acetylcholine compositions |
Apr, 2019
(4 years ago) | |
Drugs and Companies using ACETYLCHOLINE CHLORIDE ingredient
Market Authorisation Date: 22 September, 1993
Treatment: Pharm product container 1st chamber is disposed aqueous diluent sol 2nd chamber pharm active agent comprising acetylcholine,buffer in 1st cham is sufficient to buffer ph of mixed sol resulting mixture...
Dosage: FOR SOLUTION;OPHTHALMIC
MIOCHOL-E family patents
6. Prolensa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129431 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Sep, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561277 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8927606 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US9144609 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8669290 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8871813 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8754131 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US10085958 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2032
(8 years from now) | |
| US9517220 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2016 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery; Method of treating ocular inflammation
Dosage: SOLUTION/DROPS;OPHTHALMIC
PROLENSA family patents
7. Retisert patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6217895 | BAUSCH AND LOMB | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
| US6548078 | BAUSCH AND LOMB | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Apr 08, 2012 |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 08 April, 2005
Treatment: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye
Dosage: IMPLANT;INTRAVITREAL
RETISERT family patents
8. Vyzulta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6211233 | BAUSCH AND LOMB | Prostaglandin pharmaceutical compositions |
Jun, 2018
(5 years ago) | |
| US7910767 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(8 months from now) | |
| US8058467 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(8 months from now) | |
| US7273946 | BAUSCH AND LOMB | Prostaglandin derivatives |
Oct, 2025
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7629345 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(8 months from now) | |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Market Authorisation Date: 02 November, 2017
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
VYZULTA family patents
9. Zylet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4996335 (Pediatric) | BAUSCH AND LOMB | Soft steroids having anti-inflammatory activity |
Sep, 2012
(11 years ago) | |
| US5540930 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
| US5747061 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
|
US5747061 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
|
US5540930 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
Drugs and Companies using LOTEPREDNOL ETABONATE; TOBRAMYCIN ingredient
Market Authorisation Date: 14 December, 2004
Treatment: Steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists
Dosage: SUSPENSION/DROPS;OPHTHALMIC
ZYLET family patents